TriSalus Life Sciences (TLSI) announces the appointment of David Patience as Chief Financial Officer, effective July 1, 2025. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Young remains available to the Company to support an orderly transition.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- Trisalus Life Sciences Q1 2025 Earnings Call Highlights
- TriSalus Life Sciences: Strategic Developments and Revenue Growth Drive Buy Rating
- TriSalus Life Sciences management to meet virtually with Lake Street
- TriSalus Life Sciences: Strong Financial Performance and Strategic Focus Drive Buy Rating
- TriSalus Life Sciences: Promising Growth Trajectory and Strategic Focus Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue